Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 18,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Glioblastoma, GBM, Glioma
Interventions: Trans Sodium Crocetinate (TSC); Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more

Conditions: NHL
Interventions: IGN002; Biological
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Lymphoma, B-Cell
Interventions: Inotuzumab ozogamicin [CMC-544]; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Buffalo, New York + 3 more

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: GSK2126458 and GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: HIV-1 Infections
Interventions: dapivirine 4789, dapivirine gel 4759, Drug placebo; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more

Conditions: Advanced Solid Tumors
Interventions: AMG 256; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Duarte, California • Indianapolis, Indiana • St Louis, Missouri + 1 more

Conditions: Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Recombinant ADAMTS13; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Dublin, Ohio • Portland, Oregon • Houston, Texas

Conditions: Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: [18F]FPyQCP; Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography; Radiation · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: BR-DIM; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Duarte, California • Denver, Colorado + 10 more

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Interventions: ARV-393, Glofitamab; Drug
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: New Haven, Connecticut • Miami, Florida • Detroit, Michigan + 6 more

Conditions: Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase of Disease, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Recurrent Disease
Interventions: Laboratory Biomarker Analysis, Tipifarnib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2017
U.S. locations: 2
States / cities: Palo Alto, California • Rochester, New York

Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Interventions: CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: Renal Impairment, Healthy Volunteers
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Chicago, Illinois

Conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 148
States / cities: Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: veliparib, temozolomide, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions: Ad-P53, Xeloda, Keytruda, Opdivo; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Tubular Necrosis, Acute
Interventions: Multipotent Stromal Cells, Administration of MSC; Biological
Lead sponsor: AlloCure Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Advanced Malignancies, Urothelial Carcinoma, MSI-H or dMMR Solid Tumors, Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: Apatinib, Pembrolizumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions: placebo, tanezumab; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Search by objective public record fields.

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

A Study of IGN002 for Refractory NHL

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Vaccine Therapy in Treating Patients With Melanoma

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

A Study of TAK-279 in Adults With or Without Kidney Problems

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected